[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Kentucky\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":139},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,76,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641909","phase-1-cannabis-and-opioid-use-disorder-study-2-100641909",false,"NCT07661446","Cannabis and Opioid Use Disorder, Study 2","Inclusion Criteria:\n\n* Participants with moderate to severe opioid use disorder\n\nExclusion Criteria:\n\n* Individuals who do not use opioids or do not experience opioid withdrawal when they stop using opioids","ALL","18 Years","55 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.",[26,27],"Opioid Use Disorders","Cannabis Use",[29,30,31,32,33,34],"Cannabis","marijuana","opioid","opioid use disorder","opioid withdrawal","opioid interaction","NOT_YET_RECRUITING","2026-08-19",{"date":38,"type":39},"2026-08-20","ACTUAL",{"date":41,"type":20},"2026-10-01",{"date":43,"type":20},"2030-01-30",{"name":45,"class":46},"University of Kentucky","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100637145","comparing-acupuncture-vs-sham-acupuncture-for-the-management-of-hot-flashes-in-prostate-cancer-patients-receiving-hormone-therapy-100637145","NCT07594002","Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy","Inclusion Criteria:\n\n* Patients with history of prostate cancer with currently receiving hormone therapy or had received hormone therapy in the past two years\n* Hormone therapies may include androgen deprivation therapy ( ADT; e.g., leuprolide, degarelix, or relugolix) or androgen signaling inhibitors (e.g., enzalutamide, apalutamide, or darolutamide) or adrenal steroid synthesis inhibitor (e.g., abiraterone acetate).\n* Patients may also receive additional treatments such as chemotherapy, radioligand therapy or target therapy in combination with hormone therapy.\n* Reports hot flashes at least twice per day. Patients may already be taking medications for hot flashes. There is no limit on the number of hot flash medications they can be using.\n* ECOG performance status =3 (see Appendix A).\n* Patients may participate in other therapeutic clinical trials for the treatment of prostate cancer. They will remain eligible as long as they meet the eligible criteria.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.\n* Patients with a prior or concurrent malignancy are eligible for this trial.\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Patients can't travel for acupuncture\n* Patients with high bleeding tendency as determined by PI","99 Years",{"count":56,"type":20},40,[58],"NA","This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily activities, and overall quality of life.\n\nParticipants enrolled in this study will receive acupuncture treatment over a defined treatment period. The study will assess changes in hot flash frequency, severity, and quality of life using patient questionnaires and symptom diaries. Participants will complete a daily hot flash diary during selected 7-day assessment periods and quality-of-life questionnaires during study visits.\n\nThe primary goal of this study is to determine whether acupuncture may improve hot flash symptoms and related quality of life in men undergoing treatment for prostate cancer.",[61,62,63,64],"Accupuncture","Prostate Cancer","Hormone Therapy","Hot Flashes",[62,64,66],"Androgen Deprivation Therapy","RECRUITING","2026-08-15",{"date":70,"type":39},"2026-08-18",{"date":72,"type":39},"2026-08-13",{"date":74,"type":20},"2028-08-31",{"name":45,"class":46},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100610259","recovery-of-physical-function-after-critical-illness-in-older-adults-100610259","NCT07225257","Recovery of Physical Function After Critical Illness In Older Adults","RETURN: Recovery of Physical Function After Critical Illness In Older Adults","RETURN","Inclusion Criteria:\n\n* adult patients (≥40 years of age)\n* patients who have survived an ICU admission of at least 72 hours\n* diagnosis of acute lung injury or sepsis are eligible.\n\nExclusion Criteria:\n\n* individuals who were not ambulatory prior to ICU admission,\n* not expected to survive at least 6 months,\n* have a new or pre-existing brain infarct, injury, or neurological condition with deficits preventing participation in physical testing,\n* have a pre-existing geriatric syndrome that were confound recovery trajectory",true,{"count":86,"type":20},150,"OBSERVATIONAL","The proposed study is a prospective, observational study assessing the recovery of muscle and physical function in patients surviving critical illness (n =150) at hospital discharge (baseline) and repeated serially. Patients will be enrolled after life-saving modalities have been weaned near hospital discharge. Patients will participate in testing at baseline, 3-, 6-, 12-, and 24-months after hospital discharge. In a subset of patients (n = 18), muscle biopsies will be performed at baseline and then repeated once at either 12- or 24-months after hospital discharge.",[90,91],"Sepsis","Acute Lung Injury(ALI)",[93,94,95,96],"sepsis","acute respiratory failure","intensive care unit","Acquired muscle weakness","2026-05-25",{"date":99,"type":39},"2026-05-28",{"date":101,"type":39},"2026-03-11",{"date":103,"type":20},"2031-12-31",{"name":45,"class":46},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":84,"sex":15,"minAge":16,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100483539","trac-er-intervention-to-reduce-risky-alcohol-use-and-hiv-risk-100483539","NCT05576350","TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk","Evaluation of a Combined Motivational Interviewing and Ecological Momentary Intervention to Reduce Risky Alcohol Use Among Individuals Vulnerable to HIV\u002FAIDS","TRAC-ER","Inclusion Criteria:\n\n* is between the ages of 18-35 at the start of the study\n* owns a smartphone\n* has not been diagnosed with HIV\n* screens positively for at-risk alcohol use (score of 4 or higher on the AUDIT-C, OR report engaging in binge drinking at least once over the past 12 months).\n* meets criteria for pre-exposure prophylaxis (PrEP) OR is identified as being at high risk for HIV (i.e., reports history of using PrEP\u002FPEP, reports unprotected sex, etc.)\n\nExclusion Criteria:\n\n* do not speak English\n* are actively detoxifying from substances and need medical supervision\n* a score of 20 or greater on the Alcohol Use Disorders Identification Test","35 Years",{"count":115,"type":20},405,[58],"Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use. A mobile app has been developed that uses GPS tracking to determine when individuals visit \"risky\" places and then delivers a survey asking what behaviors they engaged in while at the location.\n\nThe goal of the proposed study is to use this app to enhance the Tracking and Reducing Alcohol Consumption (TRAC) intervention by delivering messages that encourage participants to employ strategies discussed during TRAC sessions when arriving at risky places. When they leave these places, they will complete a survey and breathalyzer reading in order to collect event-level self-report and biological data on alcohol use and HIV risk. If their breathalyzer result indicates alcohol use, they will receive harm reduction messaging. It is expected that combining TRAC with EMI (\"TRAC-ER\") will increase effectiveness by reinforcing topics discussed during these sessions, providing in-the-moment messaging to address triggers, and collecting real-time alcohol use data.",[119,120,121],"Risk Behavior","Alcohol Use Disorder","HIV Infections",[123,124,125,126,127,128,129],"motivational interviewing","behavior","ecological momentary intervention","EMI","TRAC","mobile","GPS","2025-03-25",{"date":132,"type":39},"2025-03-30",{"date":134,"type":39},"2024-12-09",{"date":136,"type":20},"2027-05",{"name":45,"class":46},2,""]